Investor AB’s Agile Therapeutics AGRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q2 | – | Sell |
-1,754
| Closed | -$596 | – | 10 |
|
|
2024
Q1 | $596 | Hold |
1,754
| – | – | ﹤0.01% | 10 |
|
|
2023
Q4 | $3.42K | Buy |
+1,754
| New | +$3.53K | ﹤0.01% | 10 |
|
|
2023
Q3 | – | Sell |
-1,754
| Closed | -$5.17K | – | 12 |
|
|
2023
Q2 | $5.17K | Sell |
1,754
-1
| -0.1% | -$5 | ﹤0.01% | 9 |
|
|
2023
Q1 | $19.7K | Hold |
1,755
| – | – | ﹤0.01% | 7 |
|
|
2022
Q4 | $20.2K | Hold |
1,755
| – | – | ﹤0.01% | 5 |
|
|
2022
Q3 | $26K | Hold |
1,755
| – | – | ﹤0.01% | 7 |
|
|
2022
Q2 | $103K | Hold |
1,755
| – | – | ﹤0.01% | 5 |
|
|
2022
Q1 | $737K | Hold |
1,755
| – | – | 0.02% | 5 |
|
|
2021
Q4 | $1.72M | Hold |
1,755
| – | – | 0.04% | 3 |
|
|
2021
Q3 | $3.37M | Hold |
1,755
| – | – | 0.09% | 2 |
|
|
2021
Q2 | $4.67M | Hold |
1,755
| – | – | 0.14% | 2 |
|
|
2021
Q1 | $7.3M | Hold |
1,755
| – | – | 0.25% | 2 |
|
|
2020
Q4 | $10.1M | Hold |
1,755
| – | – | 0.39% | 3 |
|
|
2020
Q3 | $10.7M | Hold |
1,755
| – | – | 0.44% | 2 |
|
|
2020
Q2 | $9.76M | Hold |
1,755
| – | – | 0.42% | 2 |
|
|
2020
Q1 | $6.53M | Hold |
1,755
| – | – | 0.35% | 2 |
|
|
2019
Q4 | $8.78M | Hold |
1,755
| – | – | 0.42% | 2 |
|
|
2019
Q3 | $4.18M | Hold |
1,755
| – | – | 0.21% | 3 |
|
|
2019
Q2 | $5.09M | Hold |
1,755
| – | – | 0.27% | 3 |
|
|
2019
Q1 | $5.3M | Hold |
1,755
| – | – | 0.31% | 3 |
|
|
2018
Q4 | $2.04M | Hold |
1,755
| – | – | 0.12% | 3 |
|
|
2018
Q3 | $1.3M | Hold |
1,755
| – | – | 0.08% | 3 |
|
|
2018
Q2 | $1.72M | Hold |
1,755
| – | – | 0.09% | 4 |
|
|
2018
Q1 | $9.02M | Hold |
1,755
| – | – | 0.53% | 2 |
|
|
2017
Q4 | $9.44M | Hold |
1,755
| – | – | 0.62% | 2 |
|
|
2017
Q3 | $15.7M | Hold |
1,755
| – | – | 1.01% | 2 |
|
|
2017
Q2 | $13.2M | Hold |
1,755
| – | – | 0.92% | 2 |
|
|
2017
Q1 | $11.3M | Hold |
1,755
| – | – | 0.8% | 2 |
|
|
2016
Q4 | $20M | Hold |
1,755
| – | – | 1.46% | 2 |
|
|
2016
Q3 | $24.5M | Hold |
1,755
| – | – | 1.76% | 2 |
|
|
2016
Q2 | $26.7M | Hold |
1,755
| – | – | 1.99% | 2 |
|
|
2016
Q1 | $21.8M | Hold |
1,755
| – | – | 1.6% | 3 |
|
|
2015
Q4 | $34.3M | Hold |
1,755
| – | – | 2.78% | 2 |
|
|
2015
Q3 | $23.7M | Hold |
1,755
| – | – | 2.1% | 3 |
|
|
2015
Q2 | $30.2M | Hold |
1,755
| – | – | 2.83% | 3 |
|
|
2015
Q1 | $32.5M | Hold |
1,755
| – | – | 2.91% | 3 |
|
|
2014
Q4 | $21.6M | Hold |
1,755
| – | – | 2.09% | 3 |
|
|
2014
Q3 | $25.6M | Hold |
1,755
| – | – | 2.71% | 3 |
|
|
2014
Q2 | $30.6M | Buy |
+1,755
| New | +$25.4M | 3.47% | 3 |
|
Investor AB's AGRX Position: Q2 2024 in Review
Investor AB sold out of Agile Therapeutics (AGRX) in Q2 2024, closing a stake of 1,754 shares — an estimated $596 sold.
Investor AB first reported a position in AGRX in Q2 2014 and held it in 39 quarters. The position peaked at $34.3M in Q4 2015. 0 funds tracked by Wall St. Rank hold AGRX as of Q2 2024.
- Investor AB reported no remaining Agile Therapeutics position as of Q2 2024 after selling out during the quarter.
- Investor AB sold 1,754 Agile Therapeutics shares in Q2 2024, an estimated $596.
- Investor AB first reported a position in Agile Therapeutics in Q2 2014 and held it in 39 quarters.
- Investor AB's Agile Therapeutics position peaked at $34.3M in Q4 2015.
- 0 funds tracked by Wall St. Rank held Agile Therapeutics as of Q2 2024.
Based on Investor AB's 13F filing for Q2 2024, filed 14 Aug 2024.